(HZNP, AFFY, CUTR) Noticeable Stock by CRWEWallStreet.com

Horizon Pharma, Inc.(NASDAQ:HZNP) announced the execution of a securities purchase agreement with a select group of institutional and accredited investors providing for a private placementfinancing. Upon the closing of the private financing, Horizon will receive gross proceeds of approximately $50.8 million resulting from the sale of 14,033,829 units at a price of $3.62125 per unit. Each unit consists of one share of Horizon’s common stock and a warrant to purchase 0.25 shares of common stock at an exercise price of $4.308 per share. The financing is expected to close on March 2, 2012 subject to standard closing conditions. JMP Securities LLC, Cowen and Company, LLC and Stifel Nicolaus Weisel served as joint-lead placement agents for the financing. Horizon Pharma, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. ************************ Affymax, Inc. (Nasdaq:AFFY) announced that it will receive a $5 million development milestone payment fromTakeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize peginesatide. The milestone is triggered by the European Medicines Agency (EMA) acceptance of the Marketing Authorization Application (MAA) for the investigational compound peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. ************************ Cutera, Inc. (Nasdaq:CUTR) announced that Kevin Connors, the Company’s President and CEO, will be presenting at the 24th Annual ROTH Conference to be held on March 11-14, 2012 at the Ritz-Carlton inLaguna Niguel, CA. Cutera’s presentation is scheduled for Tuesday, March 13, at 1:30 p.m. Pacific Time. The presentation will be available for review on the Investor Relations section of the Company’s website atwww.cutera.com. Cutera, Inc., a global medical device company, engages in the research, design, development, manufacture, marketing, sales, and service of laser and light-based systems for aesthetic and podiatric applications. ___ Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup ****************************************************************************** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more at http://crwewallstreet.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.